Informe nº Osteba D12-04. - Euskadi.net

ESTRATEGIAS TERAPÉUTICAS EN LA ESQUIZOFRENIA REFRACTARIA O ESQUIZOFRENIA RESISTENTE AL TRATAMIENTO16. Chua WL, de Izquierdo SA, Kulkarni J, MortimerA. Estrogen for schizophrenia. CochraneDatabase Sist. Rev. 2005 Oct 19; 4.17. Dose M, Hellweg R, Yassouridis A, Theison M,Emrich HM. Combined treatment of schizophrenicpsychoses with haloperidol andvalproate. Pharmacopsychiatry. 1998; 31:122–125.18. Emsley R, Myburgh C, Oosthuizen P, van RensburgSJ. Randomized, placebo-controlledstudy of ethyl-eicosapentaenoic acid as supplementaltreatment in schizophrenia. Am JPsychiatry. 2002; 159: 1.596–1.598.19. Evins AE, Fitzgerald SM, Wine L, Rosselli R,Goff DC. Placebo controlledtrial of glycineadded to clozapine in schizophrenia. Am JPsychiatry. 2000; 157: 826–828.20. Evins AE, Amico E, Posever TA, Toker R, GoffDC. D-Cycloserine added to risperidone in patientswith primary negative symptoms ofschizophrenia. Schizophr Res. 2002; 56:19–23.21. Fenton WS, Dickerson F, Boronow J, HibbelnJR, Knable M. A placebo-controlled trial ofomega-3 fatty acid (ethyl eicosapentaenoicacid) supplementation for residual symptomsand cognitive impairment in schizophrenia.Am J Psychiatry. 2001; 158: 2.071–2.074.22. Freeman MP, Hibbeln JR, Wisner KL, Davis JM,Mischoulon D, Peet M, Keck PE Jr, MarangellLB, Richardson AJ, Lake J, Stoll AL. Omega-3fatty acids: evidence basis for treatment andfuture research in psychiatry. J. ClinPsychiatry. 2006 Dec; 67(12): 1.954-67.23. Friedman JI, Adler DN, Howanitz E, Harvey PD,Brenner G, Temporini H, White L, Parrella M,Davis KL. A double blind placebo controlledtrial of donepezil adjunctive treatment to risperidonefor the cognitive impairment ofschizophrenia. Biol Psychiatry. 2002; 51:349–357.24. Foster S, Kessel J, Berman ME, Simpson GM.Efficacy of lorazepam and haloperidol forrapid tranquilization I n a psychiatric emergencyroom setting. Int Clin Psychopharmacol.1997; 12:175–179.25. Goff DC, Midha KK, Sarid-Segal O, HubbardJW, Amico E. A placebo-controlled trial offluoxetine added to neuroleptic in patientswith schizophrenia. Psychopharmacology(Berl). 1995; 117: 417–423.26. Goff DC, Henderson DC, Evins AE, Amico E. Aplacebo-controlled crossover trial of D-cycloserineadded to clozapine in patients withschizophrenia. Biol Psychiatry. 1999; 45:512–514.27. Goff DC, Tsai G, Levitt J, Amico E, Manoach D,Schoenfeld DA, Hayden DL, McCarley R, CoyleJT. A placebo-controlled trial of D-cycloserineadded to conventional neuroleptics in patientswith schizophrenia. Arch GenPsychiatry. 1999; 56:21–27.28. Growe GA, Crayton JW, Klass DB, Evans H, StrizichM. Lithium in chronic schizophrenia. AmJ Psychiatry. 1979; 136:454-5.29. Heresco-Levy U, Javitt DC, Ermilov M, MordelC, Horowitz A, Kelly D. Double-blind, placebocontrolled,crossover trial of glycine adjuvanttherapy for treatment-resistant schizophrenia.Br J Psychiatry. 1996; 169:610–617.30. Heresco-Levy U, Javitt DC, Ermilov M, MordelC, Silipo G, Lichtenstein M. Efficacy of highdoseglycine in the treatment ofenduring negativesymptoms of schizophrenia. Arch GenPsychiatry. 1999; 56:29–36.31. Heresco-Levy U, Ermilov M, Shimoni J, ShapiraB, Silipo G, Javitt DC. Placebo-controlledtrial of D-cycloserine added to conventionalneuroleptics, olanzapine, or risperidone inschizophrenia. Am J Psychiatry. 2002;159:480–482.32. Hesslinger B, Normann C, Langosch JM, KloseP, Berger M, Walden J. Effects of carbamazepineand valproate on haloperidol plasma levelsand on psychopathologic outcome inschizophrenic patients. J Clin Psychopharmacol.1999; 19:310–315.33. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL,Bartone P, Cooley S, Hammill K, Carter M, MunetzMR, Perel J. Pharmacotherapy Psychiatry.1995; 52:29–41.94